作者修正: コドン特異的な翻訳再プログラムが標的治療に対する抵抗性を促進する

¹Laboratory of Cancer Signaling, University of Liège, Liège, Belgium.
²GIGA-institute, University of Liège, Liège, Belgium.
³Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, Leuven, Belgium.
⁴Center for Cancer Biology, VIB, Leuven, Belgium.
⁵Institute for Pathology, University Hospital Cologne, Cologne, Germany.
⁶Centre for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium.
⁷Max Planck Research Group for RNA Biology, Max Planck Institute for Molecular Biomedicine, Münster, Germany.
⁸Faculty of Medicine, University of Münster, Münster, Germany.
⁹Cells-in-Motion Cluster of Excellence, University of Münster, Münster, Germany.
¹⁰Laboratory of Medical Chemistry, University of Liège, Liège, Belgium.
¹¹Department of Radiotherapy (MAASTRO)/GROW, School for Developmental Biology and Oncology, Maastricht University, Maastricht, The Netherlands.
¹²Metabolomics Core Facility, Center for Cancer Biology, VIB, Leuven, Belgium.
¹³Unit of Animal Genomics, University of Liège, Liège, Belgium.
¹⁴Medical Oncology, CHU Sart Tilman Liège, University of Liège, Liège, Belgium.
¹⁵WELBIO, University of Liège, Liège, Belgium.
¹⁶Laboratory of Cancer Signaling, University of Liège, Liège, Belgium. Pierre.Close@uliege.be.
¹⁷GIGA-institute, University of Liège, Liège, Belgium. Pierre.Close@uliege.be.
¹⁸WELBIO, University of Liège, Liège, Belgium. Pierre.Close@uliege.be.

まとめ